IPO Date: 30 Jul - 1 Aug 2024
Listing Date: 6 Aug 2024
Price Range
646 to 679
Issue Size
1856.74 Cr
Min Investment
₹14,212
Lot Size
22 Shares
Issue open date
30 Jul 2024
Issue close date
1 Aug 2024
UPI mandate deadline
1 Aug 2024 (5 PM)
Allotment finalization
2 Aug 2024
Share credit
5 Aug 2024
Listing date
6 Aug 2024
Mandate end date
16 Aug 2024
Funds Raised in the IPO | Amount |
---|---|
Overall | 1856.74 Cr |
Fresh Issue | 0 Cr |
Offer for Sale | 0 Cr |
Allotment Timeline | Details |
---|---|
Allotment Date | 2 Aug 2024 |
Allotment Link | {Link} |
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
Date | Ipo Price | GMP | Estimated Listing Price |
---|---|---|---|
6 Aug 2024 | ₹679 | ₹43 | ₹722 (6.33%) |
5 Aug 2024 | ₹679 | ₹43 | ₹722 (6.33%) |
4 Aug 2024 | ₹679 | ₹86 | ₹765 (12.67%) |
3 Aug 2024 | ₹679 | ₹99 | ₹778 (14.58%) |
2 Aug 2024 | ₹679 | ₹124 | ₹803 (18.26%) |
1 Aug 2024 | ₹679 | ₹141 | ₹820 (20.77%) |
31 Jul 2024 | ₹679 | ₹170 | ₹849 (25.04%) |
30 Jul 2024 | ₹679 | ₹177 | ₹856 (26.07%) |
29 Jul 2024 | ₹679 | ₹211 | ₹890 (31.08%) |
28 Jul 2024 | ₹679 | ₹180 | ₹859 (26.51%) |
27 Jul 2024 | ₹679 | ₹170 | ₹849 (25.04%) |
Issue Price | Listing Gain | Current Market Price | P/L |
---|---|---|---|
646 to 679 | ₹ 6084 (17.27%) | ₹ 503.6 | -25.83% |
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few. The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023). The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF). As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
Founded in | 2004 |
Managing director | |
Parent organization |
Category | Subscription (No. of times) |
---|---|
Qualified Institutional Buyers (QIBs) | 90.09 |
Non-Institutional Investors (NIIs) | 42.1 |
Retail Individual Investors (RIIs) | 20.8 |
Employee | 4.14 |
Total | 63.44 |